Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Protein Page:
RCAS1 (human)

Overview
RCAS1 May participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1- beta converting enzyme (ICE)-like proteases. Homodimer. By estrogen. Widely expressed. Expressed in ovary, testis, prostate, thymus, muscle and heart, but not in small intestine, colon, lymph nodes, or peripherical blood lymphocytes. The protein is not detected in any of the above organs. Note: This description may include information from UniProtKB.
Protein type: Membrane protein, integral; Apoptosis
Cellular Component: Golgi membrane; Golgi apparatus; focal adhesion; integral to membrane; plasma membrane; secretory granule
Molecular Function: apoptotic protease activator activity
Biological Process: regulation of cell growth
Reference #:  O00559 (UniProtKB)
Alt. Names/Synonyms: cancer associated surface antigen; Cancer-associated surface antigen RCAS1; EB9; EBAG9; estrogen receptor binding site associated, antigen, 9; Estrogen receptor-binding fragment-associated gene 9 protein; PDAF; RCAS1; Receptor-binding cancer antigen expressed on SiSo cells
Gene Symbols: EBAG9
Molecular weight: 24,377 Da
Basal Isoelectric point: 6.04  Predict pI for various phosphorylation states
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology® Total Proteins
Select Structure to View Below

RCAS1

Protein Structure Not Found.


STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  Source  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  Ensembl Gene


Modification Sites and Domains  

Modification Sites in Parent Protein, Orthologs, and Isoforms  
 

Show Multiple Sequence Alignment


 SS 

SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 MS 

MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 139 S36-p SGRGRKLsGDQItLP
0 8 T41-p KLsGDQItLPTTVDy
0 44 Y48-p tLPTTVDyssVPKQT
0 20 S49-p LPTTVDyssVPKQTD
0 7 S50-p PTTVDyssVPKQTDV
0 1 S86-p NVATQQNsLEQLEPD
0 100 Y94-p LEQLEPDyFKDMtPt
0 3 T99-p PDyFKDMtPtIRKTQ
0 10 T101-p yFKDMtPtIRKTQKI
  mouse

 
S36-p SGRGRKLsGDQItLP
T41-p KLsGDQItLPTTVDY
Y48 tLPTTVDYSSVPKQT
S49 LPTTVDYSSVPKQTD
S50 PTTVDYSSVPKQTDV
S86 NVATQQNSLEQLEPD
Y94 LEQLEPDYFKDMTPT
T99 PDYFKDMTPTIRKTQ
T101 YFKDMTPTIRKTQKI
  rat

 
S36-p SGRGRKLsGDQITLP
T41 KLsGDQITLPTTVDY
Y48 TLPTTVDYSSVPKQT
S49 LPTTVDYSSVPKQTD
S50 PTTVDYSSVPKQTDV
S86 NAAAQQNSLEQLEPD
Y94 LEQLEPDYFKDMTPT
T99 PDYFKDMTPTIRKTQ
T101 YFKDMTPTIRKTQKI
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.